ArticleEuropean journal of cancer (Oxford, England : 1990)2020

Dual Erb B Inhibition in Oesophago-gastric Cancer (DEBIOC): A phase I dose escalating safety study and randomised dose expansion of AZD8931 in combination with oxaliplatin and capecitabine chemotherapy in patients with oesophagogastric adenocarcinoma.

Anne Thomas et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.